Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Receivables - Net of $806000.0 for Q1 2026, up 278.4% year-over-year from $213000.0 in Q1 2025, and down 9.54% quarter-over-quarter from $891000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $806000.0 for Q1 2026.
- In Q1 2026, Receivables - Net rose 278.4% year-over-year to $806000.0; the TTM figure through Mar 2026 stood at $806000.0 (up 278.4% YoY), while the FY2025 annual figure was $891000.0, up 39.66% from the prior year.
- Receivables - Net for Q1 2026 stood at $806000.0, down from $891000.0 in the prior quarter.
- The five-year high for Receivables - Net was $891000.0 in Q4 2025, with the low at $77000.0 in Q1 2024.
- The 5-year median for Receivables - Net is $405000.0 (2024), against an average of $411411.8.
- The sharpest annual moves came in 2022 and 2026: Receivables - Net tumbled 99.41% in 2022, then surged 278.4% in 2026.
- Lineage Cell Therapeutics' Receivables - Net stood at $300000.0 in 2022, then soared by 148.33% to $745000.0 in 2023, then retreated by 14.36% to $638000.0 in 2024, then soared by 39.66% to $891000.0 in 2025, then declined by 9.54% to $806000.0 in 2026.
- Business Quant data shows LCTX's Receivables - Net at $806000.0 in Q1 2026, $891000.0 in Q4 2025, and $127000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 790,000.00 |
| Jun 30, 2026 | 790,000.00 |
| Mar 31, 2026 | 806,000.00 |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 891,000.00 |
| Dec 31, 2025 | 891,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Mar 31, 2024 | 77,000.00 |